Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)

Does levosimendan reduce worsening heart failure and death in patients with left ventricular failure due to an acute myocardial infarction?

Levosimendan is safe and reduces the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.